Design and Evaluation of Liposomal Carriers for Targeted Delivery of siRNA In Cancer Therapy

Abstract

Precision medicine has advanced significantly with the design and testing of liposomal carriers for the targeted administration of small interfering RNA (siRNA) in cancer therapy. In light of the introduced exploratory information and ends, this study focused on the creation and portrayal of cationic liposomes containing 3,4-DMA lipids for productive siRNA transport and quality silencing in cancer cells. Liposomes were tried for size, zeta potential, polydispersity index (PDI), and DOTAP, Chol, and PEG colipids using electrophoretic light scattering and dynamic light scattering. In request to determine which lipoplex formulations were best at complexing with siRNA, we contrasted them with controls made with Lipofectamine 2000. These formulations were viewed as powerful in gel impediment and intracellular take-up in MDA-MB-231 cells. The liposomes' selectivity and biocompatibility towards cancer cells when contrasted with ordinary HEK 293 cells were affirmed by cytotoxicity study. Remarkably, these investigations showed how well C12-DMA liposomes containing PEG might advance the quietness of the surviving quality, a protein related with cancer cell endurance. These results suggest that the developed formulations may find application in targeted gene therapy, opening up new options for the development of cancer treatment strategies. In general, this study offers encouraging perspectives on the potential of liposomal carriers as a strong platform for targeted administration of siRNA in cancer therapy, opening the door to more efficient and individualized therapeutic approaches.